227 related articles for article (PubMed ID: 30574342)
1. A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs.
Bowen JD; Kozma CM; Grosso MM; Phillips AL
Mult Scler J Exp Transl Clin; 2018; 4(4):2055217318819031. PubMed ID: 30574342
[TBL] [Abstract][Full Text] [Related]
2. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
3. Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study.
Araujo L; Geertsen SS; Amedume A; Higuchi K; van Wingerden J
Neurol Ther; 2022 Dec; 11(4):1735-1748. PubMed ID: 36152222
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database.
Boster A; Nicholas J; Wu N; Yeh WS; Fay M; Edwards M; Huang MY; Lee A
Neurol Ther; 2017 Jun; 6(1):91-102. PubMed ID: 28211024
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis.
Zhang X; Hay JW; Niu X
CNS Drugs; 2015 Jan; 29(1):71-81. PubMed ID: 25326785
[TBL] [Abstract][Full Text] [Related]
6. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis.
Halpern R; Agarwal S; Dembek C; Borton L; Lopez-Bresnahan M
Patient Prefer Adherence; 2011 Jan; 5():73-84. PubMed ID: 21423591
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data.
Nicholas J; Boster A; Wu N; Yeh WS; Fay M; Kendter J; Huang MY; Lee A
Pharmacoecon Open; 2018 Mar; 2(1):31-41. PubMed ID: 29464673
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
9. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
Chiao E; Meyer K
Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
[TBL] [Abstract][Full Text] [Related]
11. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
[TBL] [Abstract][Full Text] [Related]
12. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.
Ernst FR; Barr P; Elmor R; Wong SL
Curr Med Res Opin; 2017 Dec; 33(12):2099-2106. PubMed ID: 28906152
[TBL] [Abstract][Full Text] [Related]
13. Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States.
Araujo L; Kyatham S; Bzdek KG; Higuchi K; Greene N
Clinicoecon Outcomes Res; 2023; 15():361-373. PubMed ID: 37234086
[TBL] [Abstract][Full Text] [Related]
14. Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study.
Vieira MC; Conway D; Cox GM; Peeples M; Bensimon AG; Macheca M; Herrera V
Curr Med Res Opin; 2020 Feb; 36(2):261-270. PubMed ID: 31694401
[No Abstract] [Full Text] [Related]
15. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Lahoz R; Reynolds T; Korn JR
Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Makin C; Lahoz R; Agashivala N; Pradhan A; Capkun G; Petrilla A; Karkare SU; Balderston McGuiness C; Korn JR
Curr Med Res Opin; 2013 Dec; 29(12):1647-56. PubMed ID: 24059944
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of oral disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review.
Shahtaheri RS; Nikfar S; Khorasani E; Sabbagh-Baniazad M; Goudarzi Z; Emamikhah M
Curr J Neurol; 2020 Jul; 19(3):138-145. PubMed ID: 38011404
[No Abstract] [Full Text] [Related]
18. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
Vermersch P; Czlonkowska A; Grimaldi LM; Confavreux C; Comi G; Kappos L; Olsson TP; Benamor M; Bauer D; Truffinet P; Church M; Miller AE; Wolinsky JS; Freedman MS; O'Connor P;
Mult Scler; 2014 May; 20(6):705-16. PubMed ID: 24126064
[TBL] [Abstract][Full Text] [Related]
19. Real-World Comparative Cost-Effectiveness Analysis of Different Classes of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in Saudi Arabia.
AlRuthia Y; Balkhi B; Alkhalifah SA; Aljarallah S; Almutairi L; Alanazi M; Alajlan A; Aldhafiri SM; Alkhawajah NM
Int J Environ Res Public Health; 2021 Dec; 18(24):. PubMed ID: 34948876
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
Sanford M; Lyseng-Williamson KA
Drugs; 2011 Oct; 71(14):1865-91. PubMed ID: 21942977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
